TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Tech companies lay claim to ‘Silicon Beach’
  2. Health care law compliance complex for employers
  3. Data make strong case for 401(k)
  4. Good manners relevant when in professional setting
  5. GAO warns of health site weaknesses
  6. Underestimated income to cost insured workers
  7. Fired coal miners find employment in Wyoming
  8. Trucking firms stretch to hire drivers
  9. ‘Airbender’ bent rules of Pa. film tax credit
  10. Young watchmaker pursues lifelong fixation
  11. Sometimes, all you need is a reboot
Subscribe today! Click here for our subscription offers.